The GLP1 pharmacological agonist, liraglutide, was used via a subcutaneous injection daily for 24 weeks in glucose-intolerant NASH patients and significantly improved liver function and histological features. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.